Significant Growth in Glaucoma Surgical Device Market Expected Over the Next Five Years

September 6, 2016: By Katie Cannady

Glaucoma is the world’s second leading cause of blindness, and the disease affects more than 80 million people around the globe, according to Market Scope estimates. Diagnosis and treatment are widely available in wealthy nations, but this is not the case in many underdeveloped countries. We estimate that only 36 percent of individuals with glaucoma are diagnosed.

Global sales of products used to diagnose and treat glaucoma are expected to total $4.7 billion in 2016. Pharmaceuticals will account for the lion’s share of these revenues. Drugs currently represent the standard of care for all but the most severe glaucoma cases, but they can be expensive, require daily administration, frequently cause side effects, and often fail to limit progression of the disease. Conventional surgical techniques used to treat glaucoma, such as filtration surgery, laser, and tube shunts, also have significant limitations.

Glaucoma surgical devices account for only 8.3 percent of the global glaucoma treatment market. However, the market is poised for rapid growth over the next five years. The glaucoma surgical device market is expected to grow at a compounded annual growth rate (CAGR) of 27 percent from 2016 to 2021. The most promising developments are likely to occur with the new crop of innovative approaches that we refer to as advanced technology glaucoma surgery (ATGS) drainage devices. ATGS devices offer the promise of safer and more effective outcomes and are already leading to earlier surgical intervention in the treatment paradigm. Micro-invasive glaucoma surgery (MIGS) drainage implants make up the bulk of these ATGS devices and are expected to account for most of the growth over the next five years.

The global glaucoma surgical device market is dominated by five companies–Glaukos, Alcon, New World Medical, Abbott Medical Optics, and Ellex–each with sales exceeding $24 million. No one company accounts for more than 24 percent of the market, and only a few participate in more than one product segment. In 2016, these companies combined are expected to generate nearly two-thirds of glaucoma surgical device revenues.

Market Scope published its 2016 Glaucoma Surgical Device Report: A Global Market Analysis for 2015 to 2021 in August 2016. It is the only source for accurate and relevant information on all aspects of the glaucoma surgical device market. We cover prevalence and forecasts for glaucoma worldwide, and we discuss the ophthalmologists who treat the disease. We examine the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. We forecast product demand in units and dollars, and we analyze market shares by product category. We also discuss key strategic issues.

Market Scope has divided the glaucoma surgical device market into four broad categories: conventional glaucoma surgery (CGS) devices, advanced technology glaucoma surgery (ATGS) devices, selective laser trabeculoplasty (SLT) lasers, and disposables/instruments. This report includes market data for 2015, and we forecast market performance through 2021. Our forecast also subdivides the market into eight geographic/economic analytic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World.

Market Scope is pleased to announce the availability of its “2016 Glaucoma Surgical Device Report.” The report is in its nineth edition. Click the following link: 2016 Glaucoma Surgical Device Report to view a detailed description and table of contents for this report or call (314) 835-0600 for more information.

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022